Generate Biomedicines GENB Estimates

NASDAQ GENB
$12.35 -0.06 (-0.48%)
At close: Oct 26, 2026 · 4:00 PM EDT
Analyst Estimates

Generate Biomedicines, Inc. Revenue Estimates

Periods 20
Next Period Q3 26
Consensus 7.57 M

Analysts expect Generate Biomedicines, Inc. to report revenue of 7.57 M for Q3 26, against a range of 7.21 M to 7.93 M. The most recent reported quarter, Q2 26, came in at 6.31 M, a 24.2% beat against the 5.08 M consensus.

Metric Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) 7.22 M6.31 M--------
High Estimate 4.81 M5.42 M7.93 M7.80 M2.27 M3.15 M5.61 M6.35 M7.74 M14.44 M
Low Estimate 4.12 M4.74 M7.21 M7.12 M1.92 M2.67 M4.96 M5.55 M7.02 M12.58 M
Consensus Estimate 4.46 M5.08 M7.57 M7.46 M2.10 M2.91 M5.29 M5.95 M7.38 M13.51 M
Analyst Estimates

Generate Biomedicines, Inc. Earnings Per Share (EPS) Estimates

Periods 20
Next Period Q3 26
Consensus -0.58

Analysts expect Generate Biomedicines, Inc. to report earnings per share of -0.58 for Q3 26, against a range of -0.62 to -0.54. The most recent reported quarter, Q2 26, came in at -0.52, a 3.7% beat against the -0.54 consensus.

Metric Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28Q1 29Q2 29Q3 29Q4 29Q1 30Q2 30Q3 30Q4 30
Reported (Actual) -1.07-0.52--------
High Estimate -0.48-0.49-0.54-0.51-0.52-0.47-0.56-0.57-0.39-0.36
Low Estimate -0.56-0.59-0.62-0.59-0.62-0.53-0.64-0.61-0.47-0.42
Consensus Estimate -0.52-0.54-0.58-0.55-0.57-0.50-0.60-0.59-0.43-0.39

Generate Biomedicines, Inc. Estimates API

Pull Wall Street consensus for Generate Biomedicines, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/estimates?ticker=GENB&mode=revenue&api_key=YOUR_API_KEY